Cargando…
Ibalizumab: First Global Approval
TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)—a humanised IgG4 monoclonal antibody—as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988774/ https://www.ncbi.nlm.nih.gov/pubmed/29675744 http://dx.doi.org/10.1007/s40265-018-0907-5 |